


The proven drug effect of Zilver® PTX® at 4 years

PATIENT INFORMATION


	Randomized controlled trial	Single-arm trial	Notes
Number of patients	479	787	Over 1,000 patients in 2 trials, including the largest SFA randomized controlled trial.
Average lesion length (ZPTX) ¹	66 mm	100 mm	Moderate and long lesions treated.
Total occlusions ¹	33%	38%	High percentage of challenging lesions included in both trials.
Diabetics ¹	50%	36%	Challenging patient subset represented in both trials.
Rutherford classification ¹	2-6	2-6	Real-world patients included in both trials.
Fracture rate	3 years: 2.1% ^{2,3}	1 year: 1.5% ^{3,4}	Core-lab adjudicated.

PROVEN DRUG EFFECT AT 4 YEARS


Zilver PTX vs. optimal PTA + BMS
primary patency (PSVR < 2.0)⁵



Zilver PTX vs. optimal PTA + BMS
Freedom from TLR⁵




Provisional Zilver PTX vs. provisional BMS
Patency (PSVR < 2.0)⁵



PATENCY (PSVR < 2.0)

Year	1 ¹	2 ²	3 ³	4 ⁵
Provisional Zilver PTX	90.2%	83.4%	79.6%	75.0%
Provisional BMS	72.9%	64.1%	56.3%	57.9%

Two Zilver PTX trials



1. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. *J Am Coll Cardiol*. 2013;61(24):2417-2427.
2. Dake M. The Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 3-year results. Presented at: Vascular Interventional Advances (VIVA) 2012; October 9-12, 2012; Las Vegas, Nevada.
3. Fracture-rate data was only collected at one year in the single-arm trial. In the randomized controlled trial, fracture-rate data was collected at one and three years.
4. Dake MD, Scheinert D, Tepe G, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. *J Endovasc Ther*. 2011;18(5):613-623.
5. Ansel G. The Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 4-year results. Presented at: Vascular Interventional Advances (VIVA) 2013; October 8-11, 2013; Las Vegas, Nevada.